HELIOS: Phase 3 trial of ibrutinib in previously treated CLL/SLL

At the 20th Congress of the European Hematology Association (EHA), Paula Cramer, MD, of the University Hospital Cologne, Cologne, Germany, discusses the first results from the phase 3 HELIOS trial, which evaluated the first-in-class, oral covalent Bruton’s tyrosine kinase inhibitor, ibrutinib, in combination with bendamustine and rituximab (BR) versus BR plus placebo in patients with previously treated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).

Year of Production:
Running Time:


Comments are closed.